Guest Post from Sandro Santagata, MD, PhD: Papillary Craniopharyngioma Trial

I am pleased to present a guest post from Dr. Sandro Santagata of Brigham and Women ’s Hospital/Dana Farber Cancer Center, who writes:Our group of collaborators has recently opened a Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas that is sponsored by the Alliance for Clinical Trials in Oncology.The eligibility criteria are listed here:https://clinicaltrials.gov/ct2/show/NCT03224767The trial is based on work published in these two papers:https://www.ncbi.nlm.nih.gov/pubmed/24413733https://www.ncbi.nlm.nih.gov/pubmed/26498373I am happy to answer any questions that our colleagues may have about this trial. ssantagata@bics.bwh.harvard.edu
Source: neuropathology blog - Category: Radiology Tags: molecular studies Source Type: blogs